Multidrug resistant Salmonella has become prevalent in most of South Asia, with a frequency ranging from 50% to 80% of all Salmonella Typhi and Salmonella Paratyphi A isolated from enteric fever patients. The positivity rate of enteric fever in Bangladesh is estimated to be 3.9%. The present study was undertaken to detect multidrug resistant S. Typhi and S. Paratyphi A isolated from blood samples of enteric fever patients from a tertiary care hospital in Dhaka City. A total of 12,000 blood samples were collected from November 2022 to May 2023, from clinically suspected patients. Blood culture was positive for Salmonella in 313 samples. Out of 313 isolates, 50 were randomly selected and Salmonella genus was confirmed by PCR targeting the InvA gene. Among these 313, biochemical and serological tests detected 263 isolates as S. Typhi and 50 as S. Paratyphi A. Antimicrobial susceptibility was conducted by Kirby–Bauer method for chloramphenicol, ampicillin, co-amoxiclav, trimethoprim-sulfamethoxazole, ciprofloxacin, cefixime, cefepime, ceftriaxone, meropenem, azithromycin and colistin. MDR Salmonella, defined as a combined resistance against three first-line antimicrobial agents, ampicillin, chloramphenicol and trimethoprim-sulfamethoxazole were detected in 42 strains of S. Typhi. Moreover, all isolates except two S. Typhi and one S. Paratyphi A of Salmonella were resistant to nalidixic acid and ciprofloxacin. The emergence of MDR S. Typhi with increased ciprofloxacin resistance is likely to further complicate the therapy of typhoid fever.